Medications and Lifestyle: The Foundation of Care
At a Glance
For selected people with stable coronary stenosis, guideline-directed medical therapy—heart medicines, smoking cessation, cardiac rehabilitation, and control of blood pressure and diabetes—can reduce future risks; stents mainly help when symptoms persist or disease is high risk.
For many years, the standard response to finding a narrowed heart artery was to “fix” it with a stent or surgery. However, modern research has transformed our understanding of coronary stenosis. We now know that for most people with stable symptoms, the foundation of a long and healthy life isn’t a procedure—it is Guideline-Directed Medical Therapy (GDMT) [1][2].
What is GDMT?
GDMT is a comprehensive, evidence-based approach to treating heart disease using the most effective combinations of medications and lifestyle changes. Rather than just opening one “clogged pipe,” GDMT treats your entire circulatory system, stabilizing plaques throughout your heart to prevent future events [3][2].
(Note: GDMT is individualized. Do not start or stop medications, especially antiplatelets, without consulting your care team.)
The Core Medications
Standard medical therapy for coronary stenosis usually involves several classes of drugs, each with a specific job:
- Lipid-Lowering Therapy: Statins are the cornerstone of treatment. They don’t just lower cholesterol; they “stabilize” plaques, making them less likely to rupture [3]. For many patients, the goal is an LDL-C (bad cholesterol) of 70 mg/dL or lower, though some high-risk guidelines suggest below 55 mg/dL [4]. If statins alone aren’t enough, doctors may add ezetimibe or PCSK9 inhibitors (injectable medications) to reach these individualized targets [4][5].
- Antiplatelet Therapy: These medications, such as low-dose aspirin or clopidogrel, prevent blood cells (platelets) from sticking together. This reduces the risk of a blood clot forming at the site of a plaque [6][7].
(Antiplatelet choice and duration are highly individualized based on bleeding risk and whether you have had a stent or heart attack. Never stop taking your prescribed antiplatelet medication after a stent without your cardiologist’s explicit instruction, as this can cause a life-threatening clot.) - Anti-Anginal Medications: Drugs like beta-blockers, calcium-channel blockers, and nitroglycerin help the heart work more efficiently and reduce chest pain [8][9]. A newer option called ranolazine can help relieve pain without affecting your heart rate or blood pressure [10].
- Anti-Inflammatory Therapy: Because heart disease is an inflammatory condition, some highly selected patients may benefit from low-dose colchicine (traditionally used for gout), which has been shown in some trials to reduce the risk of future heart attacks [11][12]. This is not a routine drug for everyone and requires careful review of your kidney, liver, and drug interaction risks.
Medical Therapy vs. Stents: The ISCHEMIA Trial
One of the most important studies in modern cardiology, the ISCHEMIA trial, compared an “invasive” strategy (stents or bypass surgery plus medications) to a “conservative” strategy (medications and lifestyle changes alone) in over 5,000 patients with stable disease and moderate-to-severe ischemia [13].
The trial’s findings were groundbreaking: for these selected patients with stable disease, an initial strategy of intensive medical therapy was just as safe as stents or surgery at preventing the main composite of death or heart attacks over several years [1][13].
- The Key Difference: Stents and surgery were better at reducing the frequency of chest pain (angina) for those who had daily or weekly symptoms [14].
- The Conclusion: If your symptoms are well-controlled with medication, you are not generally at a higher risk of death by choosing to avoid a procedure. Stents are primarily used to improve your quality of life by reducing pain, not necessarily to extend your life in this specific population [1][14]. However, this does not apply to patients with ACS, left-main disease, or severe ventricular dysfunction, where procedures often provide crucial survival benefits.
Lifestyle: The Invisible Prescription
Medication works best when paired with lifestyle changes. These are not “suggestions” but are considered essential parts of GDMT [2]:
- Tobacco Cessation: Quitting smoking is arguably the single most impactful thing you can do for your heart health [2].
- Cardiac Rehabilitation: This is a supervised program of exercise and education. Research shows it significantly improves outcomes, yet it is often underused [15][16].
- Blood Pressure & Diabetes Control: Keeping your blood pressure controlled (often targeted below 140/90 mmHg or 130/80 mmHg depending on your specific risks) and managing blood sugar (such as an HbA1c <7% for some patients) are critical targets to protect your arteries from further damage [17][18]. Discuss your personalized goals with your doctor.
By embracing GDMT, you are taking an active role in protecting your heart against future problems [19].
Common questions in this guide
What does guideline-directed medical therapy mean for coronary stenosis?
Can coronary stenosis be treated without a stent?
What medicines are commonly used for coronary stenosis?
What LDL cholesterol level might be the goal with coronary stenosis?
Which lifestyle changes help manage coronary stenosis?
Is it safe to stop aspirin or clopidogrel if I feel well?
Questions to Ask Your Doctor
Curated prompts to bring to your next appointment.
- 1.Are my current LDL cholesterol and blood pressure levels at the personalized targets for my level of risk?
- 2.Am I a candidate for 'high-intensity' statin therapy, and if my LDL remains above target, should we consider adding ezetimibe or a PCSK9 inhibitor?
- 3.Based on the ISCHEMIA trial results, is my angina stable enough to continue with medical therapy alone rather than a stent or bypass?
- 4.Given my specific medical history and kidney function, would a trial of low-dose colchicine be safe and appropriate for me?
- 5.What is my personal risk of bleeding versus my risk of a heart attack when deciding on the duration of my antiplatelet therapy?
Questions For You
Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.
References
References (19)
- 1
Implications of the Landmark ISCHEMIA Trial on the Initial Management of High-Risk Patients with Stable Ischemic Heart Disease.
Vafaei P, Naderi S, Ambrosy AP, Slade JJ
Current atherosclerosis reports 2021; (23(11)):70 doi:10.1007/s11883-021-00970-z.
PMID: 34468881 - 2
2025 AHA/ACC Clinical Performance and Quality Measures for Patients With Chronic Coronary Disease: A Report of the American College of Cardiology/American Heart Association Joint Committee on Performance Measures.
Williams MS, Levine GN, Kalra D, et al.
Journal of the American College of Cardiology 2025; (85(25)):2504-2535 doi:10.1016/j.jacc.2025.02.001.
PMID: 40310322 - 3
The importance of LDL-C lowering in atherosclerotic cardiovascular disease prevention: Lower for longer is better.
Mhaimeed O, Burney ZA, Schott SL, et al.
American journal of preventive cardiology 2024; (18()):100649 doi:10.1016/j.ajpc.2024.100649.
PMID: 38576462 - 4
Invasive versus Conservative Management in Coronary Artery Disease.
Rezkalla SH, Kloner RA
Clinical medicine & research 2023; (21(2)):95-104 doi:10.3121/cmr.2023.1806.
PMID: 37407216 - 5
Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome.
Schwartz GG, Steg PG, Szarek M, et al.
The New England journal of medicine 2018; (379(22)):2097-2107 doi:10.1056/NEJMoa1801174.
PMID: 30403574 - 6
Should We Use Aspirin or P2Y12 Inhibitor Monotherapy in Stable Ischemic Heart Disease?
Chandiramani R, Mehta A, Blumenthal RS, Williams MS
Current atherosclerosis reports 2024; (26(11)):649-658 doi:10.1007/s11883-024-01234-2.
PMID: 39243345 - 7
P2Y12 Inhibitor or Aspirin Monotherapy for Secondary Prevention of Coronary Events.
Gragnano F, Cao D, Pirondini L, et al.
Journal of the American College of Cardiology 2023; (82(2)):89-105 doi:10.1016/j.jacc.2023.04.051.
PMID: 37407118 - 8
Optimal Medical Therapy for Stable Ischemic Heart Disease: Focus on Anti-anginal Therapy.
Montelaro BM, Ibrahim R, Thames M, Mehta PK
The Medical clinics of North America 2024; (108(3)):455-468 doi:10.1016/j.mcna.2023.12.006.
PMID: 38548457 - 9
Treatment of Angina: Where Are We?
Balla C, Pavasini R, Ferrari R
Cardiology 2018; (140(1)):52-67 doi:10.1159/000487936.
PMID: 29874661 - 10
Non-haemodynamic anti-anginal agents in the management of patients with stable coronary artery disease and diabetes: A review of the evidence.
Ambrosio G, Tamargo J, Grant PJ
Diabetes & vascular disease research 2016; (13(2)):98-112 doi:10.1177/1479164115609028.
PMID: 26873904 - 11
Colchicine in Coronary Artery Disease: Comparative Review of CLEAR SYNERGY, LoDoCo2 and COLCOT.
Jannink J, van Zelm AM, Chemlal S, et al.
Current atherosclerosis reports 2026; (28(1)):11 doi:10.1007/s11883-025-01382-z.
PMID: 41528549 - 12
Long-term trials of colchicine for secondary prevention of vascular events: a meta-analysis.
Samuel M, Berry C, Dubé MP, et al.
European heart journal 2025; (46(26)):2552-2563 doi:10.1093/eurheartj/ehaf174.
PMID: 40314333 - 13
Initial Invasive or Conservative Strategy for Stable Coronary Disease.
Maron DJ, Hochman JS, Reynolds HR, et al.
The New England journal of medicine 2020; (382(15)):1395-1407 doi:10.1056/NEJMoa1915922.
PMID: 32227755 - 14
Health-Status Outcomes with Invasive or Conservative Care in Coronary Disease.
Spertus JA, Jones PG, Maron DJ, et al.
The New England journal of medicine 2020; (382(15)):1408-1419 doi:10.1056/NEJMoa1916370.
PMID: 32227753 - 15
Cardiac Rehabilitation for Patients With Stable Ischemic Heart Disease Without Revascularization - Rationale and Design of a Single-Arm Pilot Study.
Seki T, Murata M, Takabayashi K, et al.
Circulation reports 2023; (5(3)):90-94 doi:10.1253/circrep.CR-22-0131.
PMID: 36909138 - 16
EUROASPIRE IV: A European Society of Cardiology survey on the lifestyle, risk factor and therapeutic management of coronary patients from 24 European countries.
Kotseva K, Wood D, De Bacquer D, et al.
European journal of preventive cardiology 2016; (23(6)):636-48 doi:10.1177/2047487315569401.
PMID: 25687109 - 17
Attainment of Guideline-Directed Medical Treatment in Stable Ischemic Heart Disease Patients With and Without Chronic Kidney Disease.
Koutroumpakis E, Gosmanova EO, Stahura H, et al.
Cardiovascular drugs and therapy 2019; (33(4)):443-451 doi:10.1007/s10557-019-06883-z.
PMID: 31123935 - 18
Optimal Medical Therapy for Stable Ischemic Heart Disease in 2024: Focus on Blood Pressure and Lipids.
Abrahams T, Nicholls SJ, Nelson AJ
The Medical clinics of North America 2024; (108(3)):441-453 doi:10.1016/j.mcna.2023.12.005.
PMID: 38548456 - 19
Outcomes According to Coronary Revascularization Modality in the ISCHEMIA Trial.
Redfors B, Stone GW, Alexander JH, et al.
Journal of the American College of Cardiology 2024; (83(5)):549-558 doi:10.1016/j.jacc.2023.11.002.
PMID: 37956961
This page is for informational purposes only and does not constitute medical advice. It explains treatment options for coronary stenosis, but your cardiology team should guide medication changes, antiplatelet use, and decisions about stents or surgery.
Get notified when new evidence is published on coronary stenosis.
We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.